Head-To-Head Review: ZIVO Bioscience (NASDAQ:ZIVO) & Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Taysha Gene Therapies and ZIVO Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	0	0	10	0	3.00
ZIVO Bioscience	0	1	0	0	2.00

Taysha Gene Therapies presently has a consensus target price of $6.60, suggesting a potential upside of 206.98%. Given Taysha Gene Therapies’ stronger consensus rating and higher possible upside, equities analysts plainly believe Taysha Gene Therapies is more favorable than ZIVO Bioscience.

Institutional & Insider Ownership

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 2.7% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 21.5% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Taysha Gene Therapies and ZIVO Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	-833.60%	-782.81%	-55.24%
ZIVO Bioscience	-11,068.75%	N/A	-677.15%

Valuation and Earnings

This table compares Taysha Gene Therapies and ZIVO Bioscience’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$15.45 million	26.03	-$111.57 million	($0.49)	-4.39
ZIVO Bioscience	$30,000.00	778.95	-$7.78 million	($3.80)	-1.86

ZIVO Bioscience has lower revenue, but higher earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Taysha Gene Therapies has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.

Summary

Taysha Gene Therapies beats ZIVO Bioscience on 9 of the 14 factors compared between the two stocks.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

About ZIVO Bioscience

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.